E Hope Weissler1, Robert M Clare2, Yuliya Lokhnygina2, John B Buse3, Shaun G Goodman4,5, Brian Katona6, Nayyar Iqbal6, Neha J Pagidipati2,7, Naveed Sattar8, Rury R Holman9, Adrian F Hernandez2,7, Robert J Mentz2,7, Manesh R Patel2,7, W Schuyler Jones2,7. 1. Division of Vascular Surgery, Duke University School of Medicine, Durham, NC, USA. 2. Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA. 3. Division of Endocrinology, University of North Carolina School of Medicine, Chapel Hill, NC, USA. 4. Canadian VIGOUR Centre, University of Alberta, Edmonton, AB, Canada. 5. Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. 6. BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA. 7. Division of Cardiology, Duke University School of Medicine, Durham, NC, USA. 8. Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK. 9. Diabetes Trials Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Abstract
AIMS: Although models exist to predict amputation among people with type 2 diabetes with foot ulceration or infection, we aimed to develop a prediction model for a broader range of major adverse limb events (MALE)-including gangrene, revascularization and amputation-among individuals with type 2 diabetes. METHODS: In a post-hoc analysis of data from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial, we compared participants who experienced MALE with those who did not. A multivariable model was constructed and translated into a risk score. RESULTS: Among the 14,752 participants with type 2 diabetes in EXSCEL, 3.6% experienced MALE. Characteristics associated with increased risk of MALE were peripheral artery disease (PAD) (HRadj 4.83, 95% CI: 3.94-5.92), prior foot ulcer (HRadj 2.16, 95% CI: 1.63-2.87), prior amputation (HRadj 2.00, 95% CI: 1.53-2.64), current smoking (HRadj 2.00, 95% CI: 1.54-2.61), insulin use (HRadj 1.86, 95% CI: 1.52-2.27), coronary artery disease (HRadj 1.67, 95% CI: 1.38-2.03) and male sex (HRadj 1.64, 95% CI: 1.31-2.06). Cerebrovascular disease, former smoking, age, glycated haemoglobin, race and neuropathy were also associated significantly with MALE after adjustment. A risk score ranging from 6 to 96 points was constructed, with a C-statistic of 0.822 (95% CI: 0.803-0.841). CONCLUSIONS: The majority of MALE occurred among participants with PAD, but participants without a history of PAD also experienced MALE. A risk score with good performance was generated. Although it requires validation in an external dataset, this risk score may be valuable in identifying patients requiring more intensive care and closer follow-up.
AIMS: Although models exist to predict amputation among people with type 2 diabetes with foot ulceration or infection, we aimed to develop a prediction model for a broader range of major adverse limb events (MALE)-including gangrene, revascularization and amputation-among individuals with type 2 diabetes. METHODS: In a post-hoc analysis of data from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial, we compared participants who experienced MALE with those who did not. A multivariable model was constructed and translated into a risk score. RESULTS: Among the 14,752 participants with type 2 diabetes in EXSCEL, 3.6% experienced MALE. Characteristics associated with increased risk of MALE were peripheral artery disease (PAD) (HRadj 4.83, 95% CI: 3.94-5.92), prior foot ulcer (HRadj 2.16, 95% CI: 1.63-2.87), prior amputation (HRadj 2.00, 95% CI: 1.53-2.64), current smoking (HRadj 2.00, 95% CI: 1.54-2.61), insulin use (HRadj 1.86, 95% CI: 1.52-2.27), coronary artery disease (HRadj 1.67, 95% CI: 1.38-2.03) and male sex (HRadj 1.64, 95% CI: 1.31-2.06). Cerebrovascular disease, former smoking, age, glycated haemoglobin, race and neuropathy were also associated significantly with MALE after adjustment. A risk score ranging from 6 to 96 points was constructed, with a C-statistic of 0.822 (95% CI: 0.803-0.841). CONCLUSIONS: The majority of MALE occurred among participants with PAD, but participants without a history of PAD also experienced MALE. A risk score with good performance was generated. Although it requires validation in an external dataset, this risk score may be valuable in identifying patients requiring more intensive care and closer follow-up.
Authors: E W Steyerberg; F E Harrell; G J Borsboom; M J Eijkemans; Y Vergouwe; J D Habbema Journal: J Clin Epidemiol Date: 2001-08 Impact factor: 6.437
Authors: Kristy Pickwell; Volkert Siersma; Marleen Kars; Jan Apelqvist; Karel Bakker; Michael Edmonds; Per Holstein; Alexandra Jirkovská; Edward Jude; Didac Mauricio; Alberto Piaggesi; Gunnel Ragnarson Tennvall; Heinrich Reike; Maximilian Spraul; Luigi Uccioli; Vilma Urbancic; Kristien van Acker; Jeff van Baal; Nicolaas Schaper Journal: Diabetes Care Date: 2015-02-09 Impact factor: 19.112
Authors: Linda S Geiss; Yanfeng Li; Israel Hora; Ann Albright; Deborah Rolka; Edward W Gregg Journal: Diabetes Care Date: 2018-11-08 Impact factor: 19.112
Authors: Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews Journal: N Engl J Med Date: 2017-06-12 Impact factor: 91.245
Authors: Curt Diehm; Jens Rainer Allenberg; David Pittrow; Matthias Mahn; Gerhart Tepohl; Roman L Haberl; Harald Darius; Ina Burghaus; Hans Joachim Trampisch Journal: Circulation Date: 2009-11-09 Impact factor: 29.690
Authors: M Engelhardt; H Bruijnen; C Scharmer; W A Wohlgemuth; C Willy; K D Wölfle Journal: Eur J Vasc Endovasc Surg Date: 2008-03-19 Impact factor: 7.069
Authors: Rury R Holman; Mary Angelyn Bethel; Jyothis George; Harald Sourij; Zoë Doran; Joanne Keenan; Nardev S Khurmi; Robert J Mentz; Abderrahim Oulhaj; John B Buse; Juliana C Chan; Nayyar Iqbal; Sudeep Kundu; Aldo P Maggioni; Steven P Marso; Peter Öhman; Michael J Pencina; Neil Poulter; Lisa E Porter; Ambady Ramachandran; Bernard Zinman; Adrian F Hernandez Journal: Am Heart J Date: 2015-12-21 Impact factor: 4.749
Authors: Premranjan P Singh; J Dawn Abbott; Manuel S Lombardero; Kim Sutton-Tyrrell; Gail Woodhead; Lakshmi Venkitachalam; Nicholas P Tsapatsaris; Thomas C Piemonte; Rodrigo M Lago; Martin K Rutter; Richard W Nesto Journal: Diabetes Care Date: 2011-02 Impact factor: 19.112
Authors: E Hope Weissler; Dennis I Narcisse; Jennifer A Rymer; Ehrin J Armstrong; Eric Secemsky; William A Gray; Jihad A Mustapha; George L Adams; Gary M Ansel; Manesh R Patel; W Schuyler Jones Journal: Vasc Endovascular Surg Date: 2020-10-23 Impact factor: 1.089